Darren J Kelly Selected Research

anthranilic acid (anthranilate)

1/2022	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment.
2/2005	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
10/2004	Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.
1/2003	Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darren J Kelly Research Topics

Disease

51	Fibrosis (Cirrhosis) 01/2022 - 01/2003
34	Diabetic Nephropathies (Diabetic Nephropathy) 01/2016 - 10/2001
19	Myocardial Infarction 01/2022 - 08/2003
17	Hypertrophy 01/2020 - 03/2002
16	Hypertension (High Blood Pressure) 01/2021 - 01/2003
15	Heart Failure 12/2019 - 08/2003
14	Albuminuria 12/2013 - 03/2002
10	Chronic Renal Insufficiency 01/2022 - 07/2010
10	Proteinuria 01/2020 - 07/2002
9	Inflammation (Inflammations) 01/2021 - 01/2007
9	Diabetic Cardiomyopathies 07/2015 - 11/2007
8	Infarction (Infarctions) 01/2018 - 08/2003
7	Cardio-Renal Syndrome 01/2021 - 11/2012
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2008
5	Diabetes Mellitus 03/2011 - 03/2002
4	Cardiomegaly (Heart Hypertrophy) 01/2018 - 08/2003
4	Cardiomyopathies (Cardiomyopathy) 12/2017 - 02/2011
4	Hypoxia (Hypoxemia) 10/2016 - 03/2003
4	Atrial Fibrillation 01/2013 - 02/2011
4	Type 2 Diabetes Mellitus (MODY) 01/2013 - 09/2005
3	Left Ventricular Dysfunction 01/2022 - 01/2011
3	Hyperglycemia 01/2016 - 02/2003
3	Glomerulonephritis 09/2011 - 01/2008
3	Retinopathy of Prematurity (Retrolental Fibroplasia) 04/2006 - 03/2003
2	Necrosis 05/2021 - 07/2010
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2017 - 08/2013
2	Cicatrix (Scar) 10/2015 - 10/2004
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2015 - 08/2007
2	Stroke (Strokes) 09/2013 - 03/2009
2	Body Weight (Weight, Body) 09/2013 - 03/2003

Drug/Important Bio-Agent (IBA)

24	CollagenIBA 01/2020 - 10/2001
17	Proteins (Proteins, Gene)FDA Link 05/2021 - 06/2002
15	Transforming Growth Factor beta (TGF-beta)IBA 01/2022 - 01/2002
11	Streptozocin (Streptozotocin)FDA Link 09/2013 - 03/2002
10	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2012 - 10/2001
9	C.I. direct red 80IBA 10/2016 - 03/2010
9	tranilastIBA 12/2013 - 01/2003
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 11/2003
8	Messenger RNA (mRNA)IBA 01/2015 - 07/2003
7	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 01/2006
6	IndicanIBA 01/2022 - 07/2010
6	salicylhydroxamic acid (SHAM)IBA 01/2018 - 08/2003
6	ThioredoxinsIBA 01/2016 - 08/2008
5	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2021 - 11/2008
5	CytokinesIBA 10/2015 - 10/2001
5	Platelet-Derived Growth FactorIBA 01/2013 - 07/2003
5	Protein Isoforms (Isoforms)IBA 09/2011 - 07/2003
5	ruboxistaurinIBA 06/2009 - 08/2005
4	anthranilic acid (anthranilate)IBA 01/2022 - 01/2003
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 03/2002
4	Perindopril FDA LinkGeneric 01/2018 - 03/2002
4	FT011IBA 01/2015 - 01/2012
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2015 - 04/2009
4	Pharmaceutical PreparationsIBA 09/2013 - 07/2002
4	Peptides (Polypeptides)IBA 01/2013 - 07/2003
4	Protein Kinase CIBA 09/2011 - 08/2005
4	urotensin IIIBA 08/2010 - 08/2003
4	Protein Kinase C betaIBA 06/2009 - 02/2003
4	OsteopontinIBA 12/2008 - 06/2002
4	Transforming Growth Factor beta1 (TGF beta 1)IBA 11/2008 - 02/2005
3	MAP Kinase Kinase Kinase 5IBA 01/2021 - 01/2020
3	Myosins (Myosin)IBA 12/2019 - 03/2013
3	Atrial Natriuretic Factor (ANF)IBA 01/2018 - 01/2012
3	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2018 - 01/2007
3	AST 120IBA 04/2015 - 01/2012
3	AngiotensinsIBA 04/2015 - 02/2004
3	Retinaldehyde (Retinal)IBA 01/2015 - 03/2003
3	N(6)-carboxymethyllysine (carboxymethyllysine)IBA 08/2013 - 09/2011
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2013 - 04/2004
3	Advanced Glycation End ProductsIBA 01/2012 - 10/2001
3	Angiotensin IIIBA 08/2011 - 11/2002
3	Epidermal Growth Factor (EGF)IBA 08/2011 - 01/2002
3	ChemokinesIBA 03/2011 - 01/2007
3	nephrinIBA 06/2009 - 07/2002
3	ReninIBA 03/2009 - 02/2003
2	rho-Associated KinasesIBA 12/2019 - 04/2008
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2019 - 04/2018
2	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2018 - 01/2017
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2018 - 02/2011
2	pimonidazoleIBA 10/2016 - 12/2008
2	Small Interfering RNA (siRNA)IBA 01/2016 - 05/2014
2	Uremic ToxinsIBA 04/2015 - 11/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2015 - 07/2010
2	3-nitrotyrosineIBA 01/2015 - 08/2013
2	RelaxinIBA 09/2013 - 07/2008
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2013 - 11/2012
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2013 - 09/2011
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2013 - 02/2012
2	Tissue Inhibitor of Metalloproteinase-1IBA 01/2013 - 07/2008
2	Endothelins (Endothelin)IBA 01/2013 - 01/2004
2	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 11/2012 - 05/2011
2	Collagen Type III (Type III Collagen)IBA 05/2012 - 12/2005
2	aliskiren FDA Link 09/2011 - 06/2011
2	EnzymesIBA 09/2011 - 06/2009
2	ErbB Receptors (EGF Receptor)IBA 08/2011 - 09/2005
2	Blood Glucose (Blood Sugar)IBA 05/2011 - 01/2003

Therapy/Procedure

19	Therapeutics 01/2022 - 07/2002
5	Nephrectomy 01/2020 - 07/2003
4	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 08/2013 - 02/2011
2	Synchrotrons 01/2021 - 03/2013